Vaccine efficacy against the B.1.351 variant appeared low in early clinical observations
In short: Researchers studying the ChAdOx1 nCoV-19 vaccine found that its protection against the B.1.351 variant of SARS-CoV-2 was notably low. Analyzing participants in a clinical trial, the study observed a vaccine efficacy of only 10.4% against this specific variant, though the results were part of an early analysis with wide confidence intervals.
The study evaluated the safety and efficacy of the vaccine in 2,026 HIV-negative adults, using laboratory assays to test serum from 25 participants against the B.1.351 variant. While the vaccine showed greater resistance to the variant in serum samples compared to placebo, the primary analysis of symptomatic illness showed limited protection. A major limitation is the wide confidence intervals, indicating high uncertainty in the efficacy estimate.
This research is critical for understanding how emerging variants might evade vaccine-induced immunity.
Why it matters: Early data suggested the ChAdOx1 vaccine provided limited protection against the B.1.351 variant.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Source: Research: Madhi et al. (2021). Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. New England Journal of Medicine. · cc-by
To cite this card, link to https://intellectplus.co.uk/app/health-research-vaccine-efficacy-against-the-b-1-351-variant-appeared-low-in.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Pandemics & epidemics · More in Health · Latest · A–Z · All topics
